Novartis revolutionizes drug discovery with Microsoft Azure AI
Novartis has partnered with Microsoft to enhance its drug discovery processes by leveraging AI technologies provided by Azure. This collaboration enables Novartis scientists to analyze extensive datasets and effectively use machine learning tools, significantly expediting the identification of viable drug candidates. The use of advanced analytical methods allows researchers to transform tasks traditionally taking months or years into processes executed within weeks or even days.
- Organization
- Novartis
- Industry
- Healthcare
- Location
- United States
- Published
- November 2021
Reported outcomes
Strategic outcomes
Primary read
Use case focus
Showing 2 of 2
- 1Drug candidate identification
- 2AI-based analytics
- Long and inefficient drug discovery timelines.
- Manual analysis of extensive chemical and biological datasets.
- High costs associated with traditional drug development methods.
- Difficulty in identifying viable and innovative drug candidates.
- Utilizing Azure's robust AI and machine learning capabilities.
- Automating data analysis to identify potential drug candidates.
- Enabling advanced analytics for faster research outcomes.
- Streamlining workflows to reduce dependency on manual processes.
- Reduced drug discovery timeline from years to weeks or days.
- Lowered associated costs in the research process.
- Enhanced capability to identify innovative treatment options.
- Improved overall efficiency in pharmaceutical research.
Architecture
Azure AI tools analyze extensive datasets and use machine learning to expedite drug candidate identification.
Sources & evidence1
The same organization appears in newer AI deployment evidence.
- Same organization re-documented as recently as 2025.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.